IL17B and neoplasm: Our results suggest a pro-tumorigenic effect of stroma-to-tumor IL-17B/IL-17RB signaling and that specific inhibition of the IL-17B receptor could be an effective therapy to suppress the metabolic tumor-stroma cooperation.